Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Caitlyn M. Martinez x
  • Refine by Access: All Content x
Clear All Modify Search
History

A 2-year-old 3.7-kg (8.1-lb) spayed female domestic longhair cat was referred to a veterinary teaching hospital because of a 1-week history of hyporexia, weight loss (moderate to marked; body condition score, 3/9), and respiratory signs. The cat was primarily an outdoor cat and had never traveled outside of Colorado.

Clinical and Clinicopathologic Findings

Physical examination findings included tachypnea (70 breaths/min) and increased respiratory effort with harsh expiratory lung sounds. Results of a CBC and serum biochemical panel were unremarkable. The cat was negative for anti-FIV antibody and FeLV antigen; no additional evidence of immunosuppression was detected. Thoracic radiography and

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

OBJECTIVE To determine pharmacokinetic and pharmacodynamic properties of the novel factor Xa inhibitor apixaban in clinically normal cats.

ANIMALS 5 purpose-bred domestic shorthair cats.

PROCEDURES A single dose of apixaban (0.2 mg/kg, PO) was administered to each cat (time 0), and blood samples were obtained at 0, 15, 30, 45, 60, 120, 240, 360, 480, and 1,440 minutes. After a 1-week washout period, another dose of apixaban (0.2 mg/kg, IV) was administered to each cat, and blood samples were obtained at 0, 5, 10, 15, 30, 45, 60, 120, 240, 360, 480, and 1,440 minutes. Apixaban concentrations in plasma were measured via liquid chromatography–tandem mass spectrometry. Pharmacodynamic effects of apixaban were determined with a commercial assay for factor × activity, which measures endogenous factor Xa activity chromogenically.

RESULTS Factor Xa was inhibited as a function of time after a single dose of apixaban administered orally or IV, and a direct inverse correlation with the plasma apixaban concentration was detected. Pharmacokinetic analysis revealed moderate clearance, short half-life, and high bioavailability for apixaban. A 2-compartment model was fit to the IV pharmacokinetic data; compartmental modeling could not be used to adequately describe the oral data because of substantial interindividual variability.

CONCLUSIONS AND CLINICAL RELEVANCE Results inticated that apixaban was an effective inhibitor of factor Xa in cats. Further studies will be needed to determine pharmacokinetics and pharmacodynamics after multidose administration, effects of cardiac disease on pharmacokinetics and pharmacodynamics, dosing recommendations, and efficacy of apixaban for use in the treatment and prevention of thromboembolic disease in cats.

Full access
in American Journal of Veterinary Research